EMERGENT BIOSOLUTIONS INC (EBS) Fundamental Analysis & Valuation

NYSE:EBS • US29089Q1058

Current stock price

8.23 USD
-0.15 (-1.79%)
At close:
8.23 USD
0 (0%)
After Hours:

This EBS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. EBS Profitability Analysis

1.1 Basic Checks

  • EBS had positive earnings in the past year.
  • In the past year EBS had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: EBS reported negative net income in multiple years.
  • In multiple years EBS reported negative operating cash flow during the last 5 years.
EBS Yearly Net Income VS EBIT VS OCF VS FCFEBS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M -400M -600M

1.2 Ratios

  • The Return On Assets of EBS (3.99%) is better than 89.94% of its industry peers.
  • EBS's Return On Equity of 10.07% is amongst the best of the industry. EBS outperforms 92.46% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 5.56%, EBS belongs to the top of the industry, outperforming 90.72% of the companies in the same industry.
Industry RankSector Rank
ROA 3.99%
ROE 10.07%
ROIC 5.56%
ROA(3y)-17.15%
ROA(5y)-10.14%
ROE(3y)-48.85%
ROE(5y)-29.65%
ROIC(3y)N/A
ROIC(5y)N/A
EBS Yearly ROA, ROE, ROICEBS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin of EBS (7.08%) is better than 89.75% of its industry peers.
  • In the last couple of years the Profit Margin of EBS has declined.
  • EBS's Operating Margin of 13.99% is amongst the best of the industry. EBS outperforms 91.68% of its industry peers.
  • EBS's Operating Margin has declined in the last couple of years.
  • With a decent Gross Margin value of 56.23%, EBS is doing good in the industry, outperforming 75.82% of the companies in the same industry.
  • EBS's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 13.99%
PM (TTM) 7.08%
GM 56.23%
OM growth 3YN/A
OM growth 5Y-13.31%
PM growth 3YN/A
PM growth 5Y-18.44%
GM growth 3Y13.88%
GM growth 5Y-3.61%
EBS Yearly Profit, Operating, Gross MarginsEBS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. EBS Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so EBS is destroying value.
  • Compared to 1 year ago, EBS has less shares outstanding
  • The number of shares outstanding for EBS has been reduced compared to 5 years ago.
  • EBS has a better debt/assets ratio than last year.
EBS Yearly Shares OutstandingEBS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
EBS Yearly Total Debt VS Total AssetsEBS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • EBS has an Altman-Z score of 1.46. This is a bad value and indicates that EBS is not financially healthy and even has some risk of bankruptcy.
  • EBS has a Altman-Z score of 1.46. This is in the better half of the industry: EBS outperforms 63.64% of its industry peers.
  • The Debt to FCF ratio of EBS is 3.65, which is a good value as it means it would take EBS, 3.65 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 3.65, EBS belongs to the best of the industry, outperforming 92.26% of the companies in the same industry.
  • EBS has a Debt/Equity ratio of 1.09. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of EBS (1.09) is worse than 76.21% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.09
Debt/FCF 3.65
Altman-Z 1.46
ROIC/WACC0.65
WACC8.62%
EBS Yearly LT Debt VS Equity VS FCFEBS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 5.01 indicates that EBS has no problem at all paying its short term obligations.
  • EBS's Current ratio of 5.01 is in line compared to the rest of the industry. EBS outperforms 55.32% of its industry peers.
  • A Quick Ratio of 2.41 indicates that EBS has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 2.41, EBS is doing worse than 68.47% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.01
Quick Ratio 2.41
EBS Yearly Current Assets VS Current LiabilitesEBS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. EBS Growth Analysis

3.1 Past

  • EBS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 583.87%, which is quite impressive.
  • EBS shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -28.18% yearly.
  • The Revenue for EBS has decreased by -28.81% in the past year. This is quite bad
  • Measured over the past years, EBS shows a very negative growth in Revenue. The Revenue has been decreasing by -13.74% on average per year.
EPS 1Y (TTM)583.87%
EPS 3YN/A
EPS 5Y-28.18%
EPS Q2Q%-960%
Revenue 1Y (TTM)-28.81%
Revenue growth 3Y-12.72%
Revenue growth 5Y-13.74%
Sales Q2Q%-23.63%

3.2 Future

  • The Earnings Per Share is expected to decrease by -26.56% on average over the next years. This is quite bad
  • Based on estimates for the next years, EBS will show a quite strong growth in Revenue. The Revenue will grow by 9.81% on average per year.
EPS Next Y-64.99%
EPS Next 2Y-62.68%
EPS Next 3Y-26.56%
EPS Next 5YN/A
Revenue Next Year-7.96%
Revenue Next 2Y-8.88%
Revenue Next 3Y21.22%
Revenue Next 5Y9.81%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
EBS Yearly Revenue VS EstimatesEBS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
EBS Yearly EPS VS EstimatesEBS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 2 -2 4 -4 6

More info and screens

Find the best growth stocksShow best growing peers

7

4. EBS Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 5.49, the valuation of EBS can be described as very cheap.
  • 98.26% of the companies in the same industry are more expensive than EBS, based on the Price/Earnings ratio.
  • EBS is valuated cheaply when we compare the Price/Earnings ratio to 25.60, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 15.67 indicates a correct valuation of EBS.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of EBS indicates a rather cheap valuation: EBS is cheaper than 95.74% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.84, EBS is valued a bit cheaper.
Industry RankSector Rank
PE 5.49
Fwd PE 15.67
EBS Price Earnings VS Forward Price EarningsEBS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 98.45% of the companies in the same industry are more expensive than EBS, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, EBS is valued cheaply inside the industry as 99.81% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 2.72
EV/EBITDA 3.97
EBS Per share dataEBS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10

4.3 Compensation for Growth

  • EBS has a very decent profitability rating, which may justify a higher PE ratio.
  • EBS's earnings are expected to decrease with -26.56% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-62.68%
EPS Next 3Y-26.56%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. EBS Dividend Analysis

5.1 Amount

  • EBS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EBS Fundamentals: All Metrics, Ratios and Statistics

EMERGENT BIOSOLUTIONS INC

NYSE:EBS (4/2/2026, 8:20:31 PM)

After market: 8.23 0 (0%)

8.23

-0.15 (-1.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-05
Inst Owners80.21%
Inst Owner Change4.68%
Ins Owners2.28%
Ins Owner Change-5.38%
Market Cap426.07M
Revenue(TTM)742.90M
Net Income(TTM)52.60M
Analysts80
Price Target12.24 (48.72%)
Short Float %17.61%
Short Ratio9.37
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)243.77%
Min EPS beat(2)-487.04%
Max EPS beat(2)974.59%
EPS beat(4)3
Avg EPS beat(4)169.91%
Min EPS beat(4)-487.04%
Max EPS beat(4)974.59%
EPS beat(8)6
Avg EPS beat(8)210.42%
EPS beat(12)6
Avg EPS beat(12)83.38%
EPS beat(16)7
Avg EPS beat(16)-126.28%
Revenue beat(2)1
Avg Revenue beat(2)-7.18%
Min Revenue beat(2)-32.31%
Max Revenue beat(2)17.94%
Revenue beat(4)2
Avg Revenue beat(4)-4.65%
Min Revenue beat(4)-32.31%
Max Revenue beat(4)17.94%
Revenue beat(8)4
Avg Revenue beat(8)2.83%
Revenue beat(12)7
Avg Revenue beat(12)8.13%
Revenue beat(16)9
Avg Revenue beat(16)5.79%
PT rev (1m)-11.11%
PT rev (3m)-11.11%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)215.56%
EPS NY rev (3m)215.56%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-20.11%
Revenue NY rev (3m)-20.11%
Valuation
Industry RankSector Rank
PE 5.49
Fwd PE 15.67
P/S 0.57
P/FCF 2.72
P/OCF 2.5
P/B 0.82
P/tB 4.95
EV/EBITDA 3.97
EPS(TTM)1.5
EY18.23%
EPS(NY)0.53
Fwd EY6.38%
FCF(TTM)3.03
FCFY36.8%
OCF(TTM)3.3
OCFY40.04%
SpS14.35
BVpS10.09
TBVpS1.66
PEG (NY)N/A
PEG (5Y)N/A
Graham Number18.46
Profitability
Industry RankSector Rank
ROA 3.99%
ROE 10.07%
ROCE 8.76%
ROIC 5.56%
ROICexc 6.73%
ROICexgc 12.12%
OM 13.99%
PM (TTM) 7.08%
GM 56.23%
FCFM 21.11%
ROA(3y)-17.15%
ROA(5y)-10.14%
ROE(3y)-48.85%
ROE(5y)-29.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-16.45%
ROICexc growth 3YN/A
ROICexc growth 5Y-14.85%
OM growth 3YN/A
OM growth 5Y-13.31%
PM growth 3YN/A
PM growth 5Y-18.44%
GM growth 3Y13.88%
GM growth 5Y-3.61%
F-Score8
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 1.09
Debt/FCF 3.65
Debt/EBITDA 2.86
Cap/Depr 14.41%
Cap/Sales 1.86%
Interest Coverage 2.09
Cash Conversion 85.43%
Profit Quality 298.1%
Current Ratio 5.01
Quick Ratio 2.41
Altman-Z 1.46
F-Score8
WACC8.62%
ROIC/WACC0.65
Cap/Depr(3y)27.25%
Cap/Depr(5y)102.87%
Cap/Sales(3y)3.19%
Cap/Sales(5y)10.89%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)583.87%
EPS 3YN/A
EPS 5Y-28.18%
EPS Q2Q%-960%
EPS Next Y-64.99%
EPS Next 2Y-62.68%
EPS Next 3Y-26.56%
EPS Next 5YN/A
Revenue 1Y (TTM)-28.81%
Revenue growth 3Y-12.72%
Revenue growth 5Y-13.74%
Sales Q2Q%-23.63%
Revenue Next Year-7.96%
Revenue Next 2Y-8.88%
Revenue Next 3Y21.22%
Revenue Next 5Y9.81%
EBIT growth 1Y227.49%
EBIT growth 3YN/A
EBIT growth 5Y-25.22%
EBIT Next Year4.68%
EBIT Next 3Y-3.42%
EBIT Next 5YN/A
FCF growth 1Y337.99%
FCF growth 3YN/A
FCF growth 5Y-16.44%
OCF growth 1Y190.63%
OCF growth 3YN/A
OCF growth 5Y-20.46%

EMERGENT BIOSOLUTIONS INC / EBS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for EMERGENT BIOSOLUTIONS INC?

ChartMill assigns a fundamental rating of 5 / 10 to EBS.


Can you provide the valuation status for EMERGENT BIOSOLUTIONS INC?

ChartMill assigns a valuation rating of 7 / 10 to EMERGENT BIOSOLUTIONS INC (EBS). This can be considered as Undervalued.


How profitable is EMERGENT BIOSOLUTIONS INC (EBS) stock?

EMERGENT BIOSOLUTIONS INC (EBS) has a profitability rating of 6 / 10.


What is the earnings growth outlook for EMERGENT BIOSOLUTIONS INC?

The Earnings per Share (EPS) of EMERGENT BIOSOLUTIONS INC (EBS) is expected to decline by -64.99% in the next year.